ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR EBITDA Margin

EBITDA as a percentage of revenue.

ProQR Therapeutics N.V.NASDAQ: PRQR

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -624.2%

EBITDA Margin was -624.2% in Q1 FY2026, down 416.1 pp from a year earlier. On a trailing-twelve-month basis it was -319.0%, down 184.3 pp year over year. Over 3 fiscal years it widened by 1328.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of -241.5% for the fiscal year ending Dec 2026, up from -242.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-624.2%-448.4 pp QoQ
Last fiscal yearDec 2025
-242.4%-114.8 pp YoY
LTMMar 2026
-319.0%-184.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-416.1 pp+4.9 pp+421.0 pp
1 year-114.8 pp+0.9 pp+115.7 pp
3 years+1328.5 pp+124.0 pp-1204.6 pp
5 years+228.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-242.4%
Year-over-year change
-114.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PRQR compares with its peers on the latest reported figures

  • PRQR's LTM Mar 2026 EBITDA Margin of -319.0% is the 4th highest of the 7 companies compared; the peer median is -752.6%.
  • Its year-over-year change of -184.3 pp is the 5th highest of 6, against a peer median of -87.2 pp.
  • Over three fiscal years its change of +1328.5 pp compares with a peer median of +327.6 pp.
PRQR Competitors Peer median
EBITDA Margin for PRQR and competitors
Company Period LTM level YoY 3-year change
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-62.6% -41.0 pp-64.2 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-148.9% -100.7 pp-100.7 pp
EDITEditas Medicine, Inc.LTM Mar 2026-258.7% +387.8 pp+719.4 pp
PRQRProQR Therapeutics N.V.LTM Mar 2026-319.0% -184.3 pp+1328.5 pp
IMMPImmutep LimitedFY2025-1246.6% -87.2 pp+17462.2 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-2873.3% -2889.4 pp—
MREOMereo BioPharma Group plcLTM Mar 2026-7858.4% ——
ACHVAchieve Life Sciences, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
ZURAZura Bio LimitedFY2025— ——
Peer median (excluding PRQR) -752.6%-87.2 pp+327.6 pp

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.34M3.59M6.51M18.91M15.28M
Cost of Revenue00002.6M
Gross Profit1.34M3.59M6.51M18.91M12.68M
Gross Margin100.0%100.0%100.0%100.0%83.0%
Research & Development42.22M50.87M25.15M36.36M40.72M
Selling, General & Admin17.37M18.65M16.24M13.66M14.12M
Operating Expenses58.55M68.75M38.37M49.38M54.84M
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
EBITDA(54.95M)(56.46M)(24.1M)(24.12M)(37.04M)
EBITDA Margin-4116.0%-1571.0%-369.9%-127.6%-242.4%
Operating Income(57.21M)(65.16M)(31.86M)(30.47M)(42.15M)
Operating Margin-4285.4%-1813.0%-489.1%-161.2%-275.9%
Interest Income5K106K2.59M3.25M2.24M
Interest Expense3.41M5.13M1.2M1.08M866.4K
Other Income / Expenses(3.47M)1.05M4.05M2.51M1.65M
Income Before Tax(60.68M)(64.11M)(27.81M)(27.96M)(40.5M)
Pre-Tax Margin-4545.5%-1783.8%-427.0%-147.9%-265.1%
Income Tax Expense117K96K(78K)(197K)18.25K
Net Income(60.74M)(64.42M)(28.12M)(27.76M)(40.52M)
Net Margin-4549.8%-1792.5%-431.7%-146.9%-265.2%
EPS (Basic)(0.96)(0.91)(0.35)(0.34)(0.38)
EPS (Diluted)(0.96)(0.91)(0.35)(0.34)(0.38)
Weighted Avg Shares64.18M71.64M81.01M81.67M105.33M
Weighted Avg Shares (Diluted)64.18M71.64M81.01M81.67M105.33M

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.